These agents have become the standard treatment for EGFR-mutated NSCLC patients with brain metastases who have developed resistance to previous EGFR-TKIs due to T790M mutation or for untreated patients receiving first-line therapy [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.